Company intelligence / Profile preview

Shanghai Benemae Pharmaceutical Corporation

Shanghai, Shanghai Municipality, Chinabenemae.com ↗

Ownership: Private
Development stage: Commercial

Overview

Benemae developed and commercialized beinaglutide, a fully human GLP‑1 analog approved in China since December 2016 for type II diabetes. The company has several pipeline programs targeting obesity and metabolic diseases at preclinical or clinical stages. Its gene engineering tandem technology underpins its innovation in peptide therapeutics. Clinical results show efficacy in glycemic control and weight loss among Chinese patients with type II diabetes.

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Recombinant polypeptidesSynthetic peptidesMonoclonal antibodies
Industry: Biotech

Drug pipeline

9 assets

beinaglutide

8 more assets in the full pipeline.

Request access →

Partnerships

No major international pharma partnerships disclosed as of latest available data.

Beyond the preview

Go deeper on Shanghai Benemae Pharmaceutical Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Benemae Pharmaceutical Corporation.

Explore the full profile